Search

Your search keyword '"Goodkin, D. E."' showing total 177 results
Start Over Author "Goodkin, D. E."
177 results on '"Goodkin, D. E."'

5. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis

Author

Goodkin, D E

Subjects
Clinical Trials as Topic, Multiple Sclerosis, Adrenocorticotropic Hormone, Humans, Interferon-beta, Glucocorticoids, Magnetic Resonance Imaging, Immunosuppressive Agents, Interferon beta-1a, Recombinant Proteins, Research Article, Interferon beta-1b
Abstract

Corticosteroids, corticotropin, azathioprine, cyclophosphamide, and IFN-beta 1b have each had a substantial effect on the care of patients with multiple sclerosis and the design of subsequent clinical trials of experimental therapeutics for MS. The use of MRI scanning and more sensitive clinical outcome measures will possibly enable us to complete clinical trials in a fraction of the time required for earlier trials. The release of Betaseron, which favorably alters the attack rate in ambulatory patients with relapsing-remitting MS has brought a sense of renewed optimism to patients with MS, their families, and their care providers. New promising therapies for chronic progressive MS and biologic products possibly capable of enhancing the effects of IFN-beta 1b in patients with relapsing MS are setting the stage for additional important therapeutic advances in this disease.

Published
1994

14. A longitudinal study of brain atrophy in relapsing multiple sclerosis

Author

Simon, J. H., primary, Jacobs, L. D., additional, Campion, M. K., additional, Rudick, R. A., additional, Cookfair, D. L., additional, Herndon, R. M., additional, Richert, J. R., additional, Salazar, A. M., additional, Fischer, J. S., additional, Goodkin, D. E., additional, Simonian, N., additional, Lajaunie, M., additional, Miller, D. E., additional, Wende, K., additional, Martens-Davidson, A., additional, Kinkel, R. P., additional, Munschauer, F. E., additional, and Brownscheidle, C. M., additional

Published
1999
Full Text
View/download PDF

20. Changes in the expanded disability status score with interferon beta-1A-treatment for relapsing multiple sclerosis

Author

Goodkin, D E, primary, Rudick, R A, additional, Jacobs, L D, additional, Cookfair, D L, additional, Campion, M, additional, Herndon, R M, additional, Richert, J R, additional, Salazar, A M, additional, Fischer, J S, additional, Granger, C V, additional, Simon, J H, additional, Alam, J J, additional, and Simonian, N A, additional

Published
1996
Full Text
View/download PDF

35. ⊃1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS.

Author

Suhy, J, Rooney, W D, Goodkin, D E, Capizzano, A A, Soher, B J, Maudsley, A A, Waubant, E, Anderson, P B, and Weiner, M W

Subjects
MULTIPLE sclerosis, MAGNETIC resonance imaging, METABOLITES, PATIENTS
Abstract

Objective: To compare brain metabolite levels in patients with primary progressive (PP) and relapsing remitting (RR) MS and controls. Hypotheses: (1) creatine (Cr), a putative marker of gliosis, is elevated and N-acetylaspartate (NAA), a putative marker of axonal density and functional integrity, is reduced in PPMS lesions and normal appearing white matter (NAWM) compared to control white matter; (2) The pattern of metabolite change in PPMS is different than in RRMS. Methods: MRI and proton magnetic resonance spectroscopic imaging (¹H MRSI) were collected from 15 PPMS patients, 13 RRMS patients, and 20 controls. Results: Cr was increased in PPMS NAWM compared to controls (P=0.035), and compared to RRMS NAWM (P=0.038). Cr was increased in focal MRI lesions from PPMS compared to lesions from RRMS (P=0.044) and compared to control white matter (P=0.041). NAA was similarly reduced in PPMS and RRMs NAWM compared to control. NAA was similarly reduced in PPMS and RRMS lesions, compared to control whitematter. Conclusions: Creatine is higher in PPMS than RRMS NAWM and focal lesions. This observation is consistent with the notion that progressive disability in PPMS reflects increased gliosis and axonal loss whereas disability in RRMS reflects the cumulative effects of acute inflammatory lesions and axonal loss. Multiple Sclerosis (2000) 6, 148–155 [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

37. Access to semantic memory in Parkinson's disease and multiple sclerosis.

Author

Beatty, William W., Monson, Nancy, Goodkin, Donald E., Beatty, W W, Monson, N, and Goodkin, D E

Abstract

The capacity to access semantic memory and the efficiency of the memory search were studied in patients with Parkinson's disease (PD) or multiple sclerosis (MS) using a modified version of the "Supermarket Test." PD and MS patients who performed normally on the Boston Naming Test generated as many specific exemplars and category labels as did controls, and these patients also searched their semantic memories as efficiently as controls. In contrast, PD and MS patients with impaired confrontational naming generated fewer specific exemplars, but a normal number of generic category labels. These naming-impaired patients searched their semantic memories less efficiently than controls. For both MS and PD patients, the efficiency of semantic memory search was significantly correlated with measures that reflect access to semantic memory (eg, performance on letter or category fluency tasks), but was not significantly related to measures of problem-solving ability derived from the Wisconsin Card Sorting Test. Inefficient search of semantic memory in MS and PD appears to arise from an inability to retrieve knowledge from semantic memory quickly or from the loss of information from semantic memory stores, rather than from impairment in the ability to formulate and deploy appropriate strategies for task solution. ( J Geriatr Psychiatry Neurol 1989; 2:153-162). [ABSTRACT FROM PUBLISHER]

Published
1989
Full Text
View/download PDF

38. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

Author

Rudick, R.A., Simonian, N.A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Goodkin, D. E., Weinstock-Guttman, B., Herndon, R. M., Mass, M. K., Richert, J. R., Salazar, A. M., Munschauer III, F. E., Cookfair, D. L., Simon, J. H., Jacobs, L. D., and Munschauer, F E 3rd

Published
1998
Full Text
View/download PDF

41. A phase I trial of solubilized DR2MBP84-102(AG284) in multiple sclerosis

Author

Goodkin, D. E., Shulman, M., Winkelhake, J., Waubant, E., Andersson, P.-B., Stewart, T., Nelson, S., Fischbein, N., Coyle, P. K., Frohman, E., Jacobs, L., Holcenberg, J., Lee, M., and Mocci, S.

Abstract

To assess the safety, tolerability, and biologic and clinical activity of a solubilized complex comprised of human leukocyte antigen—DR2 with myelin basic protein84-102(AG284)in patients with secondary progressive MS.

Published
2000

42. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis

Author

Rudick, R. A., Goodkin, D. E., Jacobs, L. D., Cookfair, D. L., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Granger, C. V., Simon, J. H., Alam, J. J., Simonian, N. A., Campion, M. K., Bartoszak, D. M., Bourdette, D. N., Braiman, J., Brownscheidle, C. M., Coats, M. E., Cohan, S. L., Dougherty, D. S., Kinkel, R. P., Mass, M. K., Munschauer, F. E., Priore, R. L., Pullicino, P. M., Scherokman, B. J., Weistock-Guttman, B., and Whitham, R. H.

Abstract

A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-la (IFNβ-1a) (Avonex, Biogen) significantly delayed progression of disability in relapsing MS patients. The primary clinical outcome was time from study entry until disability progression, defined as≥1.0 point worsening from baseline Kurtzke Expanded Disability Status Scale (EDSS) score persisting for at least two consecutive scheduled visits separated by 6 months. The objective of this study was to examine the magnitude of benefit on EDSS and its clinical significance.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results